スタンダード・バイオツールズ Company Profile

Dr. Helen McGuire from the University of Sydney will talk about the cutting-edge immune monitoring techniques introduced by her team. This method simplifies sample collection in clinical trials conducted at multiple sites, making it particularly effective for remote or depopulated areas. Seminar content: • Immune therapy response in lung cancer: Using new immune signatures related to resistance in lung cancer revealed by over 50 CyTOF panels, it is possible to predict the ineffectiveness of immune checkpoint inhibitors, making it a powerful tool for treatment decisions. • Disease detection through plasma proteome analysis: The SomaScan platform can analyze over 11,000 proteins, allowing real-time tracking of disease progression and immune responses, opening new possibilities for biomarker discovery. • Improved predictability through multi-omics data integration: By combining cell and plasma-based immune data with advanced multi-omics analysis, predictions of clinical outcomes are enhanced.